Vistica DT - Search Results

1

Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma.

Vistica DT, Krosky PM, Kenney S, Raffeld M, Shoemaker RH. Vistica DT, et al. J Pediatr Hematol Oncol. 2008 Jan;30(1):46-52. doi: 10.1097/MPH.0b013e31815d1d6f. J Pediatr Hematol Oncol. 2008. PMID: 18176180

2

Gene expression profiling of alveolar soft-part sarcoma (ASPS).

Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, Shoemaker RH. Stockwin LH, et al. Among authors: vistica dt. BMC Cancer. 2009 Jan 15;9:22. doi: 10.1186/1471-2407-9-22. BMC Cancer. 2009. PMID: 19146682 Free PMC article.

3

Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH. Vistica DT, et al. J Pediatr Hematol Oncol. 2009 Aug;31(8):561-70. doi: 10.1097/MPH.0b013e3181a6e043. J Pediatr Hematol Oncol. 2009. PMID: 19636271 Free PMC article.

4

ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.

Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH. Kenney S, et al. Among authors: vistica dt. J Pediatr Hematol Oncol. 2011 Jul;33(5):360-8. doi: 10.1097/MPH.0b013e3182002f9f. J Pediatr Hematol Oncol. 2011. PMID: 21552147 Free PMC article.

5

Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.

Covell DG, Wallqvist A, Kenney S, Vistica DT. Covell DG, et al. Among authors: vistica dt. PLoS One. 2012;7(11):e48023. doi: 10.1371/journal.pone.0048023. Epub 2012 Nov 30. PLoS One. 2012. PMID: 23226201 Free PMC article.

6

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA. Loaiza-Pérez AI, et al. Among authors: vistica dt. Mol Cancer Ther. 2004 Jun;3(6):715-25. Mol Cancer Ther. 2004. PMID: 15210858

7

Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism.

Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA. Rivera MI, et al. Among authors: vistica dt. Biochem Pharmacol. 1999 Jun 1;57(11):1283-95. doi: 10.1016/s0006-2952(99)00046-5. Biochem Pharmacol. 1999. PMID: 10230772

8

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT. Loaiza-Pérez AI, et al. Among authors: vistica dt. J Urol. 2004 Apr;171(4):1688-97. doi: 10.1097/01.ju.0000108860.03389.1b. J Urol. 2004. PMID: 15017268

9

Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.

Acton EM, Narayanan VL, Risbood PA, Shoemaker RH, Vistica DT, Boyd MR. Acton EM, et al. Among authors: vistica dt. J Med Chem. 1994 Jul 8;37(14):2185-9. doi: 10.1021/jm00040a010. J Med Chem. 1994. PMID: 8035425

10

Uptake and cytotoxicity of 9-methoxy-N2-methylellipticinium acetate in human brain and non-brain tumor cell lines.

Kenney S, Vistica DT, Linden H, Boyd MR. Kenney S, et al. Among authors: vistica dt. Biochem Pharmacol. 1995 Jan 6;49(1):23-32. doi: 10.1016/0006-2952(94)00471-w. Biochem Pharmacol. 1995. PMID: 7840779

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters